- Home
- APGE vs XENE Comparison
APGE vs XENE Comparison
Compare APGE & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APGE | XENE |
|---|---|---|
| Founded | 2022 | 1996 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 5.3B |
| IPO Year | 2023 | 2014 |
Fundamental Metrics
Financial Performance| Metric | APGE | XENE |
|---|---|---|
| Price | $82.62 | $55.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 11 |
| Target Price | ★ $109.67 | $68.55 |
| AVG Volume (30 Days) | 517.2K | ★ 782.3K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $311,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,496.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $34.34 | $28.19 |
| 52 Week High | $95.32 | $62.91 |
Technical Indicators
Market Signals| Indicator | APGE | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 46.96 | 46.00 |
| Support Level | $80.52 | $52.92 |
| Resistance Level | $84.56 | $56.66 |
| Average True Range (ATR) | 3.55 | 1.99 |
| MACD | -0.73 | -0.28 |
| Stochastic Oscillator | 15.72 | 35.37 |
Price Performance
Historical ComparisonAbout APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.